RxDoctor Payments Data

Jennifer Wright, MD

Hematology & Oncology · Austin, TXNPI 1568624831

Payments from drug & device makers

$440in general payments, 2019–2025

Across 19 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$93
  • AstraZeneca$53
  • Novartis$44
  • Apellis Pharmaceuticals, Inc.$30
  • Amgen$21
  • E.r. Squibb & Sons, L.L.C.$21
  • plus $178 from 11 others
$136in research payments, 2019–2025

Across 1 payment — averaging $135.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$136

What the payments were for

  • Food & beverage$34578%
  • Education$9522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$440 in reported general payments places this provider in the 15th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$275,114
Medicare patients
430
Services billed
22,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate20$490,706
JakafiRuxolitinib Phosphate13$337,362
Lenalidomide14$211,652
IbrancePalbociclib12$173,715
VenclextaVenetoclax11$165,332
EliquisApixaban99$73,549
Imatinib Mesylate11$54,115
Dabigatran EtexilateDabigatran Etexilate Mesylate38$5,577
Anastrozole137$1,910
Oxycodone Hcl34$1,349
Hydroxyurea40$903
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$497
Gabapentin28$394
Potassium Chloride28$393
Promethazine Hcl29$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$12$490,70620 claims
Incyte CorporationJakafi$16$337,36213 claims
PfizerIbrance, Eliquis$20$247,264111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →